Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

OBJECTIVES: Biologic disease-modifying antirheumatic drugs (bDMARDs) have revolutionised treatment and outcomes for rheumatoid arthritis (RA). The expanding repertoire allows the option of switching bDMARD if current treatment is not effective. For some patients, even after switching, disease contro...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Rheum Dis
Päätekijät: Kearsley-Fleet, Lianne, Davies, Rebecca, De Cock, Diederik, Watson, Kath D, Lunt, Mark, Buch, Maya H, Isaacs, John D, Hyrich, Kimme L
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2018
Aiheet:
Clinical and Epidemiological Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6161665/
https://ncbi.nlm.nih.gov/pubmed/29980575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2018-213378
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia